Biomolecules, Volume 12, Issue 12
2022 December - 182 articles
Cover Story: PNIs are difficult to repair, and patient outcomes often remain sub-optimal. Peripheral nerves possess an intrinsic ability to regenerate following injury, but there is a limited window for recovery before tissue atrophy obstructs regeneration and reinnervation. Preclinical studies have demonstrated ES to be a promising therapy to enhance axonal regeneration and functional recovery following injury. ES acts through retrograde action potentials to increase expression of RAGs, such as BDNF and GAP-43. Additionally, ES promotes the release of neurotrophic factors from Schwann cells which support the extending growth cone at the site of injury. Though the exact mechanism is unknown, ES promotes axonal outgrowth and survival. Early clinical evidence has demonstrated improved patient recovery. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.